title: Extravasation of oxaliplatin: an infrequent and irritant toxicity.
abstract: Oxaliplatin has been classified as an irritant drug. Less than 10 cases of oxaliplatin extravasation through a central venous access have been described to date. We present a case of extravasation through a central venous access, of the highest dose (165 mg) of oxaliplatin reported to date. We confirmed the irritant effect, and full recovery from toxicity was achieved. We describe the treatment administered and offer a review of literature.
authors.affiliation: Medical Oncology Service, Hospital de Sabadell, Corporació Sanitària Parc Taulí, Institut Universitari, Sabadell, Barcelona, Spain. cpericay@gmail.com
authors.forename: C
authors.initials: C
authors.lastname: Pericay
authors.forename: A
authors.initials: A
authors.lastname: López
authors.forename: J R
authors.initials: JR
authors.lastname: Soler
authors.forename: T
authors.initials: T
authors.lastname: Bonfill
authors.forename: E
authors.initials: E
authors.lastname: Dotor
authors.forename: E
authors.initials: E
authors.lastname: Saigí
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin; D012004:Rectal Neoplasms / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin